A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 Mg + Ezetimibe 10 Mg Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo Alone in Patients Treated With Maximally Tolerated Statin Therapy

Trial Profile

A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 Mg + Ezetimibe 10 Mg Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo Alone in Patients Treated With Maximally Tolerated Statin Therapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Bempedoic acid/ezetimibe (Primary) ; Bempedoic acid; Ezetimibe
  • Indications Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 06 Nov 2017 Status changed from planning to recruiting.
    • 26 Jul 2017 According to an Esperion Therapeutics media release, additional design details for this study will be provided upon initiation by the fourth quarter of 2017, with top-line results expected by the end of 2018.
    • 05 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top